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Abstract
Background: Tyrosine-kinase inhibitor (TKI) targeting angiogenesis improves the prognosis of patients with
metastatic renal cell carcinoma (RCC), but its effect is temporary. In order to understand the mechanism by which
RCC acquires resistance to TKI, we investigated the change of glucose accumulation in RCC by FDG PET/CT when
they demonstrated progression disease (PD) against TKI.
Methods: We monitored the FDG accumulation in RCC of 38 patients treated with TKI by 162 PET/CT sequentially until
they were judged to demonstrate PD. Standardized uptake value (SUV), a simplified index of tissue FDG accumulation
rate, was measured, and the sequential changes of max SUVmax (the highest SUV in an individual patient) was
analyzed. Additionally, the expression of glucose transporter 1 (GLUT-1) and associated proteins in 786-O cells cultured
under hypoxia were analyzed.
Results: The 10 patients with RCC which FDG accumulation was accelerated after beginning of TKI treatment
demonstrated PD soon. The other 28 patients with RCC which FDG accumulation was suppressed by TKI showed longer
progression-free survival (3.6 months vs 6.5 months, P = 0.0026), but this suppression in most cases (96%) was temporary
and FDG accumulation was accelerated when tumor demonstrated PD. Interestingly, the FDG accumulation at PD was
higher than that before TKI treatment in the half cases. The acceleration of FDG accumulation was suppressed by
following treatment by mammalian target of rapamycin (mTOR) inhibitor. Additionally, in vitro assay demonstrated that
the expression of GLUT-1 was increased in the RCC cells surviving under hypoxia condition via mTOR pathway.
Conclusions: The acceleration of glucose accumulation dependent on mTOR in RCC assessed by FDG PET/CT
demonstrated acquisition of resistance to TKI. FDG PET/CT had potential as an assessment method monitoring not only
the initial response but also following status of RCC during TKI treatment.
Trial registration: UMIN0000008141, 11 Jun 2012. This trial was retrospectively registered.
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Background
Renal cell carcinoma (RCC) is the most common type of
kidney cancer and accounts for 2–3% of all cancers cases
[1, 2]. About 30% patients are diagnosed as metastatic
disease and 20–40% of patients with localized disease
treated by curative nephrectomy develop metastases [3].
The standard systematic therapies for metastatic RCC
had been mainly cytokines including interferon-α and
interleukin-2 for a long time, and the outcome was far
from satisfactory [4, 5]. With the elucidation of the
oncogenic mechanisms of RCC, tyrosine-kinase inhibi-
tors (TKIs) targeting vascular endothelial growth factor
(VEGF) receptors such as sunitinib and sorafenib, were
developed and the prognosis of patients with metastatic
RCC was improved [6–8].
The anti-tumor mechanism of TKs is suppressing the
biological activity of RCC by inhibiting angiogenesis. In
the phase III studies for these TKI, only 2–31% of pa-
tients with tumors showed a partial response (PR) or
better as defined by RECIST criteria [6, 7]. Practically,
certain RCCs treated with TKIs do not show an obvious
reduction in tumor size, but do enter long-term dor-
mancy. Therefore, to evaluate TKI response, it is not
enough to merely assess the change in tumor volume by
conventional computed tomography (CT) imaging. In
this era of molecular targeting therapeutics, a novel
index for assessing the biological response of RCC to
TKI treatment is desirable.
18F-2-fluoro-2-deoxyglucose positron emission tomog-
raphy/computed tomography (FDG PET/CT) is a func-
tional imaging technique evaluating glucose metabolic
status, which can be used as an index of the biological
activity of cancer. We have been investigating the useful-
ness of standardized uptake value (SUV) evaluated by
FDG PET/CT, which is a semiquantitative simplified
measurement of the tissue FDG accumulation rate, as an
index for assessing the biological activity of cancer.
We first found that pretreatment maximum SUVmax
(max SUVmax), which was the highest SUV in all RCC
lesions in individual patients, could predict the survival
of patients with advanced RCC [9, 10]. Subsequently, we
reported that patients with RCC whose max SUVmax
decreased 20% or more one month after beginning TKI
treatment showed long progression-free survival (PFS)
[11]. In this study, we investigated the change of max
SUVmax when RCC demonstrated progression of dis-
ease (PD) against TKI treatments defined by RECIST cri-
teria, in order to understand the mechanism how RCC
acquires resistance to TKI treatment.
Methods
Patients and interventions
The patients planning to undergo TKI therapy for
pathologically proven metastatic RCC at Yokohama City
University Hospital (Yokohama, Japan) and affiliated
institutions between June 2008 and July 2013 were en-
rolled in this prospective study. Patients with uncon-
trolled diabetes mellitus (FBS > 150 mg/dl), other known
malignancies, or who were treated systemically within
the last four weeks were excluded.
Seventy-two patients were initially enrolled in this
study. Of these, 34 were eliminated: 23 patients showing
stable disease (SD) stopped TKI treatment due to an ad-
verse event, change of treatment strategy, at their re-
quest, general prostration, or other disease; 4 patients
showed SD on the last observation day; and 7 patients
were diagnosed as PD by unplanned CT scan due to
some symptom, and were not evaluated by PET/CT.
Thus, participants in the study were 38 patients who
continued treatment with TKI and were evaluated by
FDG PET/CT sequentially until their RCC showed PD
as defined by the Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.1 criteria [12] (Fig. 1).
Imaging
FDG PET/CT was performed before TKI treatment, one
month after beginning TKI treatment, and then every
three months. Occasionally, the timing of FDG PET/CT
assessment was modified for clinical or social reasons. Pa-
tients fasted for at least 6 h prior to intravenous injection
of 18F FDG. PET/CT images were obtained using a single
PET/CT system (Aquiduo 16; Toshiba Medical Systems,
Tokyo, Japan) at the Yokohaha City University Hospital.
The details about the condition of PET/CT examination
and methods how to determine Standardized uptake value
(SUV) were described in our previous report [10]. The
highest SUV in an individual RCC lesion and the highest
SUV in all RCC tumors of an individual patient were de-
fined as SUVmax and max SUVmax, respectively. Tumor
size responses were evaluated by the RECIST version 1.1
[12]. Two experienced physicians, who were blinded to
the clinical data examined each image.
Fig. 1 Patient disposition of this clinical trial monitoring renal cell
carcinoma by FDG PET/CT during TKI treatment until tumor
demonstrated progression disease
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In vitro assay
786-O cells were purchased from American Type Culture
Collection (Manassas, VA, USA). These cell lines were
maintained in DMEM containing 10% FCS at 37 °C under
21% O2 concentration before analysis under specific con-
ditions. The 786-O cells were cultured under either 21%
O2 concentration or 5% O2 concentration with or without
20nM of rapamycin, purchased from Sigma (St. Louis,
MO, USA) for 2 days before harvesting. Cultured cells
were harvested under appropriate conditions. Cells were
washed twice with ice cold phosphate-buffered saline
(PBS), lysed in ice cold buffer consisting of 20 mM Tris
(pH 8.0), 137 mM NaCl, 10% glycerol, 0.1% SDS, 0.5%
Nonidet P-40, 100 mM sodium fluoride, 200 mM sodium
orthovandate, 1 mM EGTA, 2 mM phenylmethylsulfonyl
fluoride, 1 μg/ml leupeptin, and 3 μg/ml aprotinin, then
centrifuged (30 min, 4 °C, 14,500Xg). Following quantita-
tion, 30 μg of lysates was subjected to SDS-PAGE on ap-
propriate gel, and electorotransferred to Immobilon-P
(Millipore, Bedford, MA, USA). After blocking the mem-
brane with 5% albumin, Western blotting was performed
and detected with an ECL detection system (Amersham
Int., UK). Anti-human HIF-2α antibodies were purchased
from Novus Biological (Littleton, CO, USA). Anti-GLUT1
antibodies were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Anti-Cyclin D1 antibodies
were purchased from PharMingen (San Diego, CA, USA).
Anti-actin antibodies were purchased from Sigma (St.
Louis, MO, USA).
Statistical analysis
PFS time was calculated from the date TKI treatment
began to the date on which RCC demonstrated PD, as de-
fined by RECIST criteria version 1.1 [12]. PFS was esti-
mated by the Kaplan-Meier method, and compared using
the log-rank test. The impact of SUVmax change on the
diameter change of tumors was analyzed by two-sided
Mann-Whitney’s U test. All statistical analyses were car-
ried out with SPSS software (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
A total of 38 patients (32 males and 6 females) were ana-
lyzed in this study (Table 1, Fig. 1). Median age was
65 years (range 32–82). There were 25 patients with re-
current disease and 13 with stage IV disease. Of the 25
patients with recurrent disease, the 12 patients had re-
currence within 5 years after nephrectomy, and the
other 13 patients did after more or 5 years. Pathological
examination revealed 32 cases of clear cell carcinoma, 5
of papillary, and 1 of unclassified renal cell carcinoma.
The number of metastases in individual patients was 1
to 10 (median 3.0). Thirty-two patients had undergone
nephrectomy, while 23 had not undergone previous
systematic therapies. The diameter of primary carcinoma
was 2.7 to 11.8 cm (median 6.0). Of 24 primary carcin-
oma which detailed pathological findings could con-
firmed, 13 (54%) included tumor necrosis. Ten patients
had undergone cytokine therapies, 2 cytokine and soraf-
enib, 1 sorafenib, 1 chemotherapy, and 1 temsirolimus.
These previous treatments had ended more than 4 weeks
before the pretreatment evaluation by FDG PET/CT.
For this study, 20 patients were treated with sorafenib,
and 18 with sunitinib. The median PFS of all cases was
5.4 months (range, 0.9 to 32.3).
The patients were evaluated by FDG PET/CT 2 to 13
times (median 4 times). The total number of FDG PET/
CT evaluation was 162.
Change of FDG accumulation during TKI treatment
We investigated the change of FDG accumulation focus-
ing on max SUVmax, which was the highest SUV in all
RCC lesions in individual patients (Table 2). The pre-
treatment max SUVmax of all patients ranged from 2.3
to 16.1 (median 6.8). In 28 cases (74%), max SUVmax
decreased after the start of TKI treatment (Fig. 2a and
b); in 10 cases (26%), it increased (Fig. 2c). The median
PFS of the 28 cases with decreasing max SUVmax was
6.5 months (95% CI 5.8–7.2 months), while that of the
10 cases with increasing max SUVmax was 3.6 months
(95% CI 1.5–5.7 months). This difference was statisti-
cally significant (log-rank P = 0.0026).
In the 28 cases with decreasing max SUVmax, the me-
dian date when SUVmax reached its nadir was 61 days.
In 14 cases (50%), max SUVmax showed a nadir at the
Table 1 Characteristic of patients
Age 32–82 y.o. (median 65 y.o.)
Gender Male 32 Female 6
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evaluation 1 month after the start of TKI. The median
decreasing ratio of SUVmax at the nadir compared with
that before treatment was 28% (1–100). Four cases
showed PD on the first evaluation after the start of TKI
treatment despite the decrease in max SUVmax (Fig. 2b).
The other 24 cases continued TKI treatment, and the
max SUVmax increased after nadir in 23 cases (96%)
(Fig. 2a and Fig. 3). Max SUVmax in 12 cases (52%) in-
creased before cancer showed PD, and that in other 11
cases increased on the same examination when cancer
Table 2 Patients and sequential change of max SUVmax








PFS (month) Number of PET/CT
evaluation
1 70′s sorefanib favorable 8.1 4.8 9.5 15.0 7
2 60′s sorefanib intermediate 8.2 8.0 8.0 3.2 3
3 50′s sunitnib intermediate 3.9 not decrease 4.0 4.1 3
4 50′s sunitnib intermediate 9.1 0.0 6.2 26.1 13
5 70′s sorefanib intermediate 5.3 2.7 4.6 21.0 9
6 60′s sorefanib intermediate 7.2 5.5 6.3 5.5 4
7 30′s sunitnib favorable 16.1 10.4 15.0 7.8 6
8 60′s sunitnib poor 14.3 12.2 12.2 0.9 2
9 80′s sunitnib intermediate 5.1 not decrease 6.4 2.2 2
10 50′s sunitnib intermediate 5.8 4.2 6.8 7.4 4
11 60′s sunitnib intermediate 8.2 3.4 7.0 6.1 4
12 70′s sorefanib intermediate 2.3 not decrease 4.4 3.6 3
13 80′s sorefanib intermediate 6.9 0.0 7.6 18.5 7
14 50′s sunitnib favorable 5.2 3.6 5.1 19.4 5
15 50′s sunitnib favorable 12.5 4.5 7.8 4.8 3
16 60′s sorefanib favorable 5.2 4.8 7.1 26.2 9
17 70′s sorefanib intermediate 6.5 5.2 5.7 6.5 3
18 60′s sorefanib favorable 4.1 3.6 4.6 6.9 4
19 50′s sorefanib favorable 5.8 4.5 7.8 22.3 7
20 70′s sunitnib intermediate 9.1 3.6 8.1 17.4 7
21 50′s sorefanib poor 9.5 not decrease 12.0 1.4 2
22 60′s sorefanib intermediate 7.4 not decrease 8.8 3.6 3
23 50′s sunitnib intermediate 8.2 5.5 5.5 0.9 2
24 70′s sorefanib intermediate 9.4 7.5 8.5 6.2 4
25 70′s sorefanib intermediate 7.0 5.9 7.6 4.2 3
26 60′s sunitnib poor 8.2 6.4 6.6 3.4 3
27 60′s sorefanib intermediate 5.2 not decrease 6.5 7.0 4
28 70′s sunitnib intermediate 8.4 6.2 7.2 10.7 5
29 50′s sunitnib poor 9.1 9.0 9.0 0.9 2
30 60′s sorefanib favorable 5.6 4.0 4.8 6.9 4
31 50′s sunitnib intermediate 11.0 not decrease 12.8 1.5 2
32 70′s sunitnib intermediate 6.4 4.2 7.0 6.5 4
33 60′s sunitnib intermediate 10.6 10.3 10.3 1.0 2
34 60′s sorefanib intermediate 5.5 not decrease 6.0 4.7 3
35 60′s sorefanib intermediate 10.1 not decrease 13.3 0.9 2
36 60′s sunitnib intermediate 3.7 not decrease 4.8 9.9 5
37 70′s sorefanib favorable 3.9 2.2 4.6 6.5 3
38 60′s sunitnib intermediate 7.9 5.2 6.7 2.9 4
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showed PD. The time lag between max SUVmax in-
crease and PD was 0–476 days (median 47 days). In 33
of the 38 cases (87%), max SUVmax increased until RCC
showed PD (Fig. 3). A comparison of max SUVmax at
PD and before TKI treatment showed that the SUVmax
at PD was higher in 19 of the 38 cases (50%).
Next, we investigated the change of the highest SUV in
individual RCC lesions (SUVmax) in the 32 patients who
had two or more RCC lesions in order to know whether
multiple lesions in one patient showed similar or inde-
pendent responses to TKI treatment. In 13 of 32 cases
(41%), the SUVmax of one lesion increased more than
10% while that of the other decreased more than 10%
compared with the SUVmax in the previous evaluation.
To reveal the association between FDG accumula-
tion and anatomical change in each lesion, we fo-
cused on the 123 lesions which SUVmax changed
more than 20% compared with previous examination.
Of the 60 lesions which SUVmax increase more than
20%, 34 lesions (57%) demonstrated the enlargement
Fig. 2 The sequential change of SUVmax during TKI treatment in 38 cases: a 24 cases showed decrease of max SUVmax and continued TKI
treatment. b Four cases showed PD on the first evaluation after the start of TKI treatment despite the decrease in max SUVmax. c 10 cases
showed increase of max SUVmax. The vertical axis shows SUVmax of individual RCC lesions. In cases with more than three RCC lesions, we used
the SUVmax in the three lesions where SUVmax was highest in the pretreatment evaluation. The horizontal axis represents time of FDG PET/CT
evaluation. “Pre” means pretreatment evaluation; numbers refer to number of months after TKI treatment started
Fig. 3 The sequential change of max SUVmax during TKI treatment
in all 38 cases was summarized
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of diameters simultaneously, 14 (23%) did not change
and other12 (20%) reduced. Otherwise, of 63 lesions
which SUVmax decrease, 39 lesions (62%) demon-
strated the reduction of diameters simultaneously, 13
(21%) did not change and other 11 lesions (17%) grew
larger. There was significant difference between these
two groups (P < 0.001).
The imaging of a practice case was shown in Fig. 4
and 5.
The acceleration of glucose accumulation during TKI
treatment was suppressed by mTOR inhibitor
Of 33 cases with their max SUVmax increasing during
TKI treatment, 6 cases was sequentially treated by
everolimus, an oral mTOR inhibitor. Interestingly, the
max SUVmax of the all 6 cases was decreased by evero-
limus, oral mammalian target of rapamycin (mTOR)
inhibitor as shown in Fig. 6a. In order to disclose the
mechanism how FDG accumulation was accelerated in
RCC when oxygen supply was suppressed by TKI inhi-
biting angiogenesis and the association between this
mechanism and mTOR, the expression of protein associ-
ated with oncogenesis in 786-O cells, human clear cell
RCC cultured under hypoxia was investigated. The ex-
pression of glucose transporter-1 (GLUT-1), Cyclin D,
and hypoxia-inducible factor 2α (HIF-2 α) was acceler-
ated in the 786-O cells that survived under hypoxic
conditions. Additionally, the overexpression of these
proteins induced by hypoxia was suppressed when 786-
O cells were cultured under the same hypoxic conditions
but with rapamycin, a classical mTOR inhibitor (Fig. 6b).
These in vitro results suggested that mTOR acitivtiy
could be involved in the increase of FDG accumulation
in RCC induced during TKI treatment.
Discussion
We previously reported that patients with advanced RCC
in which max SUVmax was decreased 1 month after begin-
ning TKI treatment had long PFS [11]. Several other inves-
tigators have reported the usefulness of FDG PET/CT
evaluation for assessing the response to TKI treatment
[13–15]. These results suggested that FDG accumulation
could be an index of the biological response to TKI of ad-
vanced RCC. These previous reports, however, focused on
the early response to TKI. In our study, we followed pa-
tients treated with TKI by FDG PET/CT until RCC showed
PD defined by RECIST criteria, to clarify the association be-
tween sequential change of glucose accumulation and ac-
quisition of resistance to TKI treatment. This is the first
report to reveal the sequential change of FDG accumula-
tion from the beginning to the end of TKI treatment.
We first focused on the response to TKI treatment,
and found that the max SUVmax of RCC decreased in
28 of 38 patients (74%). The PFS of these patients was
longer than that of the 10 RCC patients whose max
SUVmax did not decrease. These results confirmed a
previous report that FDG PET/CT was useful for evalu-
ating the early biological response to TKI treatment.
Next, we focused on the 24 patients who continued
TKI treatment after their max SUVmax showed nadir.
The max SUVmax increased in 23 of 24 patients (96%)
when RCC was judged to be PD. Adding the 10 cases
with increasing max SUVmax after the start of TKI, the
max SUVmax in 33 of our 38 total cases (87%) increased
when the RCC was judged as PD. Additionally, the max
SUVmax at PD was higher than that before treatment
began in 19 patients (50%). Additionally, this acceler-
ation was suppressed by the following treatment by
everolimus, oral mTOR inhibitor. These data suggested
9.1 11.0 1.2 2.2 0.1 2.4 2.4
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Fig. 4 The imaging of a practice case: 70’s-year-old patient with sternum, thoracic vertebrae, and ischium bone metastases (#20). The SUVmax of
all bone metastases decreased temporally and increased before tumor was judged as PD. Fusion images were upper lanes. The number means
SUVmax of each lesion. CT images were lower lanes. “Pre” refers to pretreatment evaluation; “M” refer to month after TKI treatment started
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that the acceleration of glucose uptake associated with
mTOR pathway played an important role in acquisition
of RCC resistance to TKI.
To know the association of the acceleration of glucose
uptake during TKI treatment and mTOR, we observed the
expression of protein associated with glucose accumulation
in human RCC cells under hypoxic conditions, mimicking
the condition of RCC tissue suppressed angiogenesis by
TKI treatment. In the 786-O cells, overexpression of
GLUT-1 that facilitated the transport of glucose over a
plasma membrane was induced under hypoxic conditions.
It is well known that the accumulation of HIF induced by
alteration of the Von Hippel-Lindau (VHL) gene causes
clear cell RCC, and HIF regulates the expression of various
genes involved in energy metabolism, angiogenesis, cell
proliferation, cell mortality and other biological processes
including GLUT-1 and cyclin D [16, 17]. Interestingly, the
overexpression of not only GLUT-1 but HIF and cyclin D
was overexpressed under hypoxia condition and these over-
expression was suppressed by rapamycin, classical mTOR
inhibitor. These results suggested that the overexpression
of various protein necessary for adapting to hypoxia condi-
tion, including GLUT-1 was dependent on mTOR pathway.
Recently, three deferent basic research groups reported the
novel resistance mechanism of cancer to anti-angiogenic
therapy [18–20]. They revealed that the cancer cells ad-
justed their glucose metabolic status by mTOR pathway
regulating the expression of molecule associated with glu-
cose and lactate uptake and acquired the resistance to
hypoxia condition induced by anti-angiogenic therapy.
Jiménez-Valerio G et al. demonstrated that overexpression
of GLUT-1 induced by hypoxia condition acted important
roles for resistance to anti-angiogenic therapy in RCC by
xenograft model and in vitro assay [18]. Allen E et al. [19]
and Pisarsky L [20] reported the similar mechanism in
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Fig. 5 The imaging of a practice case: 70’s-year-old patient with lung and pancreas (head and tail) metastases treated by sorafenib (#1). The
SUVmax of lung metastasis had suppressed during treatment, but the SUVmax of pancreas head metastasis increased before tumor was judged
as PD. Fusion images were upper lanes. The number means SUVmax of each lesion. CT images were lower lanes. “Pre” refers to pretreatment
evaluation; “M” refer to number of month after TKI treatment started
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Fig. 6 Accelerated FDG accumulation during TKI treatment can be dependent on mTOR activity. a 50’s-year-old patient with liver metastases (#23). The
FDG accumulation of liver metastasis that accelerated during 4 months of sunitinib treatment was suppressed by 1 month of everolimus treatment. b The
expression of GLUT-1, Cyclin D, and HIF-2 α was accelerated in the 786-O cells that survived under a hypoxic condition. The overexpression of
these proteins induced by hypoxia was suppressed by 20nM rapamycin
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respectively. Our in vitro data matched these reports,
and our clinical results that the acceleration of FDG
accumulation demonstrated acquisition of resistance
to anti-angiogenic therapy suggested that this novel
resistance mechanism identified by basic research acted
practically in human cancer treated by angiogenesis
inhibitor. It was of course that this mechanism could not
explain all of resistance mechanism of RCC to TKI
treatment. Various resistance mechanisms of cancer to
anti-angiogenic therapy were previously reported from
many investigators [21].
Finally, we examined the difference of biological re-
sponse among multiple RCC lesions in individual patients.
We analyzed the sequential change (increase or decrease)
of SUVmax in the 2 RCC lesions in 4 patients, and that in
the 3 lesions showing the highest SUVmax among all
lesions before treatment in 28 patients who had 3 or more
RCC lesions. Interestingly, all lesions showed the same
pattern, whether it was an increase or decrease (parallel
pattern), in only 9 of the 32 cases (28%). In 13 of 32 cases
(41%), the SUVmax of one lesion increased more than
10%, while that of the other lesion decreased more than
10%, compared with the SUVmax in the earlier evaluation.
Additionally, the lesion that showed max SUVmax chan-
ged during TKI treatment in 14 of 32 patients (44%).
These results implied that the biological responses of indi-
vidual lesions were independent in most patients with
multiple RCC metastases. This difference could be caused
by the heterogeneity of RCC in individual patients, which
Gerlinger et al. revealed by genetic analysis [22]. The het-
erogeneous response suggested that systemic evaluations,
for example, assessment using blood biomarker, are insuf-
ficient for evaluating the response of RCC, and that im-
aging biomarker evaluating the response of individual
RCC lesions like FDG PET/CT are necessary.
To the best of our knowledge, this is the first report to
evaluate the usefulness of monitoring RCC response by
FDG PET/CT sequentially during TKI therapy, focusing
on the acquisition of resistance to treatment. Although
the number of patients analyzed in this study was lim-
ited, we revealed that sequential monitoring by FDG
PET/CT has potential as an imaging biomarker to allow
more effective TKI use. As TKIs can cause various
adverse events and be an economic burden on patients,
such knowledge could be quite useful. Further study
targeting a large number of patients is necessary.
Conclusions
These data indicate that FDG PET/CT has potential as
an assessment method for evaluating the resistance
acquisition of RCC to TKI treatment. The increase of
glucose accumulation dependent on mTOR can be one
of the mechanisms by which RCC acquires resistance to
TKI treatment.
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